Acasti Pharma Cash on Hand 2014-2024 | GRCE

Acasti Pharma cash on hand from 2014 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Acasti Pharma Annual Cash on Hand
(Millions of US $)
2024 $23
2023 $28
2022 $44
2021 $61
2020 $14
2019 $26
2018 $6
2017 $8
2016 $8
2015 $8
2015 $
2014 $23
2014 $
2013 $5
2013 $
Acasti Pharma Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $19
2024-03-31 $23
2023-12-31 $25
2023-09-30 $27
2023-06-30 $22
2023-03-31 $28
2022-12-31 $31
2022-09-30 $35
2022-06-30 $38
2022-03-31 $44
2021-12-31 $46
2021-09-30 $51
2021-06-30 $58
2021-03-31 $61
2020-12-31 $28
2020-09-30 $12
2020-06-30 $12
2020-03-31 $14
2019-12-31 $19
2019-09-30 $20
2019-06-30 $19
2019-03-31 $26
2018-12-31 $35
2018-09-30 $5
2018-06-30 $10
2018-03-31 $6
2017-12-31 $10
2017-09-30 $4
2017-06-30 $6
2017-02-28 $8
2016-11-30 $4
2016-08-31 $6
2016-05-31 $6
2016-03-31 $6
2016-02-29
2015-12-31 $11
2015-09-30 $12
2015-06-30 $14
2015-03-31 $16
2014-12-31 $18
2014-09-30 $20
2014-06-30 $21
2014-03-31 $23
2014-02-28
2013-12-31 $3
2013-09-30 $4
2013-06-30 $4
2013-03-31 $5
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00